Novartis has launched two trials pitching Cosentyx head-to-head with AbbVie’s Humira and one of its own biosimilars in a bid to increase its presence in a highly competitive market. Cosentyx ...

Novartis is expanding its prospects in cardiometabolic ... Anthos already has clinical trial results topping Xarelto. A Phase 2 test of abelacimab was stopped early in 2023 due to “overwhelming ...

Even as Novartis takes home a partial win in court tied to its key blockbuster Entresto, the Swiss drugmaker continues to ...

An ultra-rare kidney disease that can become life-threatening now has its first FDA-approved therapy. The affirmative regulatory decision is the third for Novartis’s Fabhalta, building up the ...

In November, Isis Pharmaceuticals (Carlsbad, CA) announced the departure of its longstanding partner, Novartis Pharmaceuticals (Basel, Switzerland), leaving the small biotech company to underwrite ...

In this article, we are going to take a look at where Novartis AG (NYSE ... and distribute diagnostic tools and tests, takes the term "defensive" a step further than practically any other industry.

STAND found no benefit over placebo on VOC rates for both doses of Adakveo on test – 5 mg/kg and 7.5 mg/kg, given as a 30-minute infusion once a month – which Novartis said was "inconsistent ...